Indegene financials

Latest results Q2 FY27 · Jul–Sep 2026
Revenue
₹1,122cr+39.6% on Q2 FY26
Net profit
₹112cr+10.0% on Q2 FY26
EBITDA margin
16.6%−0.9 pts on Q2 FY26
EPS
₹4.67+9.6% on Q2 FY26

Quarterly results

Every quarter ›
₹ croreQ2 FY27Q2 FY26Change
Revenue1,122804+39.6%
EBITDA186141+32.1%
EBITDA margin16.6%17.5%−0.9 pts
Profit before tax147133+10.7%
Net profit112102+10.0%
EPS₹4.67₹4.26+9.6%

Over time

Q2 FY27 · Jul–Sep 2026latest
Revenue₹1,122 crNet profit₹112 crNet margin10.0%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024
14,405———
1,1611,4001,531985
0.00.00.0403
13,244———
4,1313,5112,8392,590
—+23.6%+9.6%—
683619534505
16.5%17.6%18.8%19.5%
511493454429
411401407337
10.0%11.4%14.3%13.0%
₹17.09₹16.68₹16.91₹14.33
—−1.4%+18.0%—
—651442508
—−44.3−30.0−10.7
607607412497
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

INDGN₹598.95

Indegene Ltd.

· Pharma & Health
₹ CrorePeersSYNGENELTTSGRANULESJUBLPHARMAKIMSERISEMCUREONESOURCEMcap ₹14,405 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization———14,404.7
- Cash, Equiv & ST Investments985.11,530.71,400.31,160.5
+ Total Debt403.10.00.00.0
Enterprise Value———13,244.2
Revenue2,589.62,839.33,510.54,130.9
Growth %, YoY—+9.6+23.6—
EBITDA505.4534.3619.0683.0
Margin %19.5218.8217.6316.53
EBIT429.3454.1492.6511.1
Net Income336.7406.7401.1411.1
Margin %13.0014.3211.439.95
EPS, Adj (current shares)14.3316.9116.6817.09
Growth %, YoY—+18.0-1.4—
Cash from Operations507.7441.9650.8—
Capital Expenditures-10.7-30.0-44.3—
Free Cash Flow497.0411.9606.5606.5
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Indegene financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Indegene (NSE: INDGN) had a market capitalisation of ₹14,272 crore at the 29 October 2026 close (₹593.45 a share), a PE ratio of 34.7 on the last four quarters' profit and a price-to-book ratio of 4.25. In FY26 its consolidated net profit was ₹401 crore on revenue of ₹3,511 crore; in Q2 FY27 (July–September 2026) it was ₹112 crore, up 10.0% year on year. It had no borrowings on 30 September 2026.

Indegene Q2 FY27 results
filed 29 October 2026
Share price used
₹593.45 · 29 October 2026 close
Latest balance sheet
30 September 2026
Shareholding pattern
30 September 2026

Indegene at a glance · consolidated

Market cap
₹14,272 Crat ₹593.45 · 29 Oct close
PE ratio (last 4 quarters)
34.735.6 on FY26 profit
Price to book (PB)
4.25book value ₹139.64 a share
ROE (FY26)
13.9%−6.2 pts vs FY25ROCE 15.7%
Debt to equity
0.00net cash ₹1,256 Cr
FII holding
12.40%+2.5 pts vs 30 Jun 2026no promoter group
Dividend yield
0.38%₹2.25 a share in 12 months
Net worth
₹3,358 Cr+17.2% vs 30 Sep 202530 September 2026
Free cash flow (FY26)
₹607 Cr+47.2% vs FY25

Questions

What is the Indegene PE ratio today?

Indegene's PE ratio is 34.7 at the 29 October 2026 close (₹593.45 a share): a market capitalisation of ₹14,272 crore divided by consolidated net profit of ₹411 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit (₹401 crore) it is 35.6.

What is the Indegene net worth?

Indegene's net worth — shareholders' equity in its consolidated balance sheet — was ₹3,358 crore on 30 September 2026, up 17.2% from ₹2,866 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹14,272 crore at the 29 October 2026 close.

What is the Indegene book value per share?

Indegene's book value per share was ₹139.64 on 30 September 2026: shareholders' equity of ₹3,358 crore divided by the 24.05 crore shares in issue, up 17.0% from ₹119.40 a year earlier. The share price at the 29 October 2026 close was ₹593.45.

What is the Indegene PB ratio (price to book value)?

Indegene's price-to-book (PB) ratio is 4.25 at the 29 October 2026 close: a market capitalisation of ₹14,272 crore divided by shareholders' equity (book value) of ₹3,358 crore on 30 September 2026. That is a book value of ₹139.64 per share against a share price of ₹593.45.

What is the Indegene ROE and ROCE?

In FY26, Indegene's return on equity (ROE) was 13.9% and its return on capital employed (ROCE) was 15.7%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 20.1% and ROCE 19.3%.

What is the Indegene dividend yield?

Indegene's dividend yield is 0.38% at the 29 October 2026 close: dividends of ₹2.25 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹593.45. They were ₹2.25 on 31 July 2026.

What is the Indegene market cap?

Indegene's market capitalisation was ₹14,272 crore at the 29 October 2026 close: 24.05 crore shares at ₹593.45 each.

Is Indegene debt free?

Yes. Indegene had no borrowings on 30 September 2026 (consolidated balance sheet), and it held ₹1,256 crore of cash, bank balances and current investments.

What is the Indegene debt to equity ratio?

Indegene's debt-to-equity ratio was 0.00 on 30 September 2026: no borrowings against total equity of ₹3,358 crore. A year earlier, on 30 September 2025, it was 0.00.

What is the Indegene EPS?

Indegene's basic earnings per share (EPS) were ₹16.72 in FY26, against ₹17.15 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹17.12.

What is the Indegene dividend in 2026 and its record date?

In 2026, Indegene has declared one dividend: ₹2.25 with record date 31 July 2026.

What is the Indegene promoter holding?

Indegene has no promoter group: on 30 September 2026 promoters held 0% of its shares, according to the shareholding pattern filed with NSE. Foreign portfolio investors held 12.40% and domestic institutions 15.82%.

What is the Indegene shareholding pattern?

On 30 September 2026, Indegene's shares were held by foreign portfolio investors (FII/FPI) 12.40%, domestic institutions (DII) 15.82% (including mutual funds at 12.25%) and retail and other non-institutional investors 71.77%. Over the year, FII holding was up 1.10 percentage points from 11.30% and DII holding was up 8.86 percentage points from 6.96%.

What are the Indegene latest quarterly results?

Indegene's latest results are for Q2 FY27 (July–September 2026), filed on 29 October 2026: consolidated net profit ₹112 crore, up 10.0% from ₹102 crore in Q2 FY26; revenue from operations ₹1,122 crore, up 39.6% year on year.

How does the Indegene PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit, Indegene's PE ratio is 35.6, the second highest of the four: Syngene International 50.8, LTTS 34.7 and Granules India 34.9, a peer average of 40.1. Each is the company's market capitalisation at that price divided by its FY26 net profit.

What is the Indegene free cash flow?

In FY26, Indegene generated ₹651 crore of cash from operations and spent ₹44.3 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹607 crore. In FY25 it was ₹412 crore.

What is the Indegene revenue and profit in FY26?

In FY26 (April 2025–March 2026), Indegene's consolidated net profit was ₹401 crore, down 1.4% from ₹407 crore in FY25, on revenue from operations of ₹3,511 crore (up 23.6%).

When are the Indegene next results?

Indegene has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.

How does Indegene compare with its peers?

On FY26 consolidated figures, against Syngene International, LTTS and Granules India: Indegene's operating margin of 14.0% is the third highest of the four (Syngene International 12.5%, LTTS 14.5%, Granules India 16.6%; peer average 14.5%); its return on equity of 13.9% is the second highest of the four (Syngene International 6.6%, LTTS 20.4%, Granules India 13.5%; peer average 13.5%).

Indegene vs Syngene International: how do they compare?

In FY26, Indegene earned net profit of ₹401 crore on revenue of ₹3,511 crore, against ₹317 crore on ₹3,739 crore for Syngene International. Indegene's operating margin was 14.0% (Syngene International 12.5%) and its return on equity 13.9% (Syngene International 6.6%). At the 29 October 2026 close, Indegene's market capitalisation was ₹14,272 crore against ₹16,091 crore for Syngene International, and its PE ratio on FY26 profit 35.6 against 50.8.

Where do these Indegene figures come from?

From Indegene's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.